The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion.
Marco Padilla-RodriguezSara S ParkerDeanna G AdamsThomas WesterlingJulieann I PuleoAdam W WatsonSamantha M HillMuhammad NoonRaphaël GaudinJesse Scott AaronDaoqin TongDenise J RoeBeatrice KnudsenGhassan MouneimnePublished in: Nature communications (2018)
Estrogen promotes growth of estrogen receptor-positive (ER+) breast tumors. However, epidemiological studies examining the prognostic characteristics of breast cancer in postmenopausal women receiving hormone replacement therapy reveal a significant decrease in tumor dissemination, suggesting that estrogen has potential protective effects against cancer cell invasion. Here, we show that estrogen suppresses invasion of ER+ breast cancer cells by increasing transcription of the Ena/VASP protein, EVL, which promotes the generation of suppressive cortical actin bundles that inhibit motility dynamics, and is crucial for the ER-mediated suppression of invasion in vitro and in vivo. Interestingly, despite its benefits in suppressing tumor growth, anti-estrogenic endocrine therapy decreases EVL expression and increases local invasion in patients. Our results highlight the dichotomous effects of estrogen on tumor progression and suggest that, in contrast to its established role in promoting growth of ER+ tumors, estrogen has a significant role in suppressing invasion through actin cytoskeletal remodeling.
Keyphrases
- estrogen receptor
- cell migration
- breast cancer cells
- postmenopausal women
- replacement therapy
- signaling pathway
- poor prognosis
- end stage renal disease
- bone mineral density
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- magnetic resonance
- magnetic resonance imaging
- pseudomonas aeruginosa
- peritoneal dialysis
- computed tomography
- escherichia coli
- bone marrow
- chronic kidney disease
- genome wide
- papillary thyroid
- contrast enhanced
- squamous cell
- human health
- cell therapy
- case control